Disease · EFO_1001366

mastodynia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. mastodynia. Diseases, record EFO_1001366. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001366

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: mastodynia; Open Targets
Open Targets ID: EFO_1001366; Open Targets
Other names: breast pain, mammalgia, mastalgia; Open Targets
MeSH: D059373; MeSH
Highest stage of its drugs: Phase 3, for 3 of its 8 drugs, from ClinicalTrials.gov; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TAMOXIFEN	CHEMBL83	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
IODINE	CHEMBL1201225	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
TOREMIFENE	CHEMBL1655	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VITAMIN E	CHEMBL3989727		Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
CABERGOLINE	CHEMBL1201087	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
PENTOXIFYLLINE	CHEMBL628	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets39

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ESR1	Estrogen receptor	2	Estrogen receptor alpha modulator; Estrogen receptor modulator	Phase 3	https://conductscience.org/library/genes/2099	Drugs and targets
ADORA2A	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/135	Drugs and targets
ADORA2B	Adenosine A2 receptor	1	Adenosine A2 receptor antagonist	Phase 2	https://conductscience.org/library/genes/136	Drugs and targets
DRD2	D(2) dopamine receptor	1	Dopamine D2 receptor agonist	Phase 2	https://conductscience.org/library/genes/1813	Drugs and targets
ESR2	Estrogen receptor	1	Estrogen receptor modulator	Phase 3	https://conductscience.org/library/genes/2100	Drugs and targets
NR3C1	Glucocorticoid receptor	1	Glucocorticoid receptor agonist	Phase 2	https://conductscience.org/library/genes/2908	Drugs and targets
PDE10A	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 2	https://conductscience.org/library/genes/10846	Drugs and targets
PDE1A	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 2	https://conductscience.org/library/genes/5136	Drugs and targets
PDE1B	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 2	https://conductscience.org/library/genes/5153	Drugs and targets
PDE1C	3',5'-cyclic phosphodiesterase	1	3',5'-cyclic phosphodiesterase inhibitor	Phase 2	https://conductscience.org/library/genes/5137	Drugs and targets

1 to 10 of 39

See all 39 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT06029673	Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss	Phase 2	69	2025-10-03	Lactation Suppressed	CABERGOLINE	Its record names the disease	ClinicalTrials.gov
NCT06404775	External Mastalgia-oil Versus Oral Tamoxifen in Premenopausal Women with Severe Mastalgia	Phase 3	456		Mastalgia	TAMOXIFEN	Its record names the disease	ClinicalTrials.gov
NCT00275600	Randomized Clinical Trial of Vitamin E and Evening Oil of Primrose for the Managment of Breast Pain	Phase 2/3	82		Cyclical Breast Pain	VITAMIN E	Open Targets' reading of its record	ClinicalTrials.gov
NCT03715413	Analgesic Efficacy of Pulsed Radiofrequency in Non-cyclic Mastalgia	Phase 2	64		Breast Fibroadenoma	DEXAMETHASONE, LIDOCAINE, TAMOXIFEN	Its record names the disease	ClinicalTrials.gov
NCT00188669	The Use of Pentoxifylline and Vitamin E in the Treatment of Chronic Breast Pain	Phase 2	48		Breast Neoplasms	PENTOXIFYLLINE, VITAMIN E	Its record names the disease	ClinicalTrials.gov
NCT00534846	The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia	Phase 3	10		Breast Pain	TOREMIFENE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cabergoline vs Placebo: deaths from any cause	0 of 34	0 of 35	69	NCT06029673	Trial comparisons
Cabergoline vs Placebo: serious adverse events	0 of 34	0 of 35	69	NCT06029673	Trial comparisons
Cabergoline vs Placebo: Number of Participants Reporting Breast Pain	16 of 32	30 of 34	66	NCT06029673	Trial comparisons
Cabergoline vs Placebo: Number of Participants Reporting Significant Bother From Side-effects	1 of 32	1 of 34	66	NCT06029673	Trial comparisons
Cabergoline vs Placebo: Number of Participants Experiencing Side-effects	26 of 32	31 of 34	66	NCT06029673	Trial comparisons
Cabergoline vs Placebo: Number of Participants Reporting Significant Bother From Breast Pain	1 of 32	7 of 34	66	NCT06029673	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
41538804	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001366

GET https://conductscience.org/api/diseases/v1/EFO_1001366/targets?page=2

API reference For AI assistants